Pharma Inc gets back to life beyond Covid

In FY23, the company is targeting 130 drug launches in the emerging markets, of which 30 would be in India.


For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company’s US business. Cipla’s ‘One India’ strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.

ET Intelligence Group: The June quarter results announced by three leading Indian pharma companies – Sun Pharma, Dr Reddy’s Labs (DRL) and Cipla – last week have some key takeaways for investors.

Normalisation of Covid revenues: The base quarter of June 2021 was impacted by the second wave of the Covid-19 pandemic with companies’ domestic market performance driven by the sale of Covid medication. That business has now gotten normalised. For

  • SAVE

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Back to top button